XML 53 R42.htm IDEA: XBRL DOCUMENT
v3.25.4

WARRANTS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Equity [Abstract] |
Schedule of Warrants Outstanding | The Company had the following series of warrants outstanding (in thousands, except per-share values) as of December 31, 2025, and 2024, all of which are exercisable:
|  | December 31, |  |  |  |  |  |
Warrant Series |  | 2025 |  |  | 2024 |  |  | Exercise Price |  |  | Expiration Date
RTI Global ("RTI") Warrants |  |  | — |  |  |  | 1,511 |  |  | $ | 5.56 |  |  | January 17, 2025
Public Warrants |  |  | 5,715 |  |  |  | 5,720 |  |  | $ | 11.50 |  |  | March 17, 2026 (1)
Private Warrants |  |  | 199 |  |  |  | 199 |  |  | $ | 11.50 |  |  | March 17, 2026 (1)
Series A Warrants |  |  | 17,757 |  |  |  | 17,857 |  |  | $ | 11.50 |  |  | March 17, 2026 (1)
Series B Warrants |  |  | 3,064 |  |  |  | 3,064 |  |  | $ | 11.50 |  |  | December 1, 2030
Series C Warrants |  |  | 5,000 |  |  |  | 5,000 |  |  | $ | 11.50 |  |  | December 1, 2030
Total warrants, issued and outstanding |  |  | 31,735 |  |  |  | 33,351 |  |  |  |  |  |
__________ (1) During February 2026, the Company entered into amended warrant agreements, which, in part, extended the expiration dates related to the Public and Private Warrants and the Series A Warrants as described in Note 19 - Subsequent Events.
Summary of Warrant (Benefit)/Expense | Warrant (benefit)/expense recognized during the years ended December 31, 2025, 2024 and 2023 is presented in the following table:
|  | Year Ended December 31, |
(in thousands) |  | 2025 |  |  | 2024 |  |  | 2023 |
RTI Warrants |  | $ | (1,291 | ) |  | $ | 8,672 |  |  | $ | (2,233 | )
Private Warrants |  |  | (161 | ) |  |  | 178 |  |  |  | (519 | )
Series A Warrants |  |  | (47,121 | ) |  |  | 41,294 |  |  |  | (31,072 | )
Series B Warrants |  |  | (4,719 | ) |  |  | 13,666 |  |  |  | — |
Series C Warrants |  |  | (8,450 | ) |  |  | 7,800 |  |  |  | — |
Change in fair value of warrants |  | $ | (61,742 | ) |  | $ | 71,610 |  |  | $ | (33,824 | )

X
- Definition Summary of warrant expense (benefit). + References No definition available. + Details
Name: | pct_SummaryOfWarrantExpenseBenefitTableTextBlock
Namespace Prefix: | pct_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration